翰宇藥業(300199.SZ):與碳雲智肽簽署GLP-1R/GIPR/GCGR三重激動劑多肽創新藥物聯合開發協議
格隆匯5月12日丨翰宇藥業(300199.SZ)公佈,2025年5月9日,深圳翰宇藥業股份有限公司召開第六屆董事會第四次會議,審議通過了《關於簽署<GLP1R/GIPR/GCGR三重激動劑多肽創新藥物聯合開發協議>的議案》。同意公司與深圳碳雲智肽藥物科技有限公司(以下簡稱“碳雲智肽”)就GLP-1R/GIPR/GCGR三重激動劑多肽創新藥物簽署聯合開發協議。基於前期合作成果,爲進一步推動項目進展,雙方擬深化合作,計劃聯合開發多肽創新藥物,多肽藥物給藥劑型包括但不限於注射劑、口服制劑等,應用於體重控制等代謝性疾病治療領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.